Statin use in COPD patients is associated with a reduction in mortality: A national cohort study

Primary Care Respiratory Journal

Volumn 21, Issue 1, 2012, Pages 35-40

  Lawes, Carlene MM ^a   Thornley, Simon ^a   Young, Robert ^a   Hopkins, Raewyn ^a   Marshall, Roger ^a   Chan, Wing Cheuk ^b   Jackson, Gary ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Division of Medicine Emergency and Integrated Care   (New Zealand)

^c Health Partners Consulting Group   (New Zealand)

Author keywords

COPD; Epidemiology; Mortality; Observational study; Statins

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FUROSEMIDE; GLYCERYL TRINITRATE; INSULIN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NICORANDIL; ORAL ANTIDIABETIC AGENT; PERHEXILINE; SIMVASTATIN;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNIC GROUP; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; NEW ZEALAND; OUTCOME ASSESSMENT; PRESCRIPTION; SEX;

EID: 85027928310     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2011.00095     Document Type: Article

References (33)

1. Broad J, Jackson R. Chronic Obstructive Pulmonary Disease and Lung Cancer in New Zealand. A report commissioned by the Asthma and Respiratory Foundation of New Zealand (Inc.) and the Thoracic Society of Australia and New Zealand, New Zealand Branch. http://www.asthmafoundation.org.nz/files/PDF-files/COPD/thoracic_rpt_nov2003.pdf, 2003.
2. Tobias M, on behalf of the New Zealand Burden of Disease Study Team. The Burden of Disease and Injury in New Zealand. Wellington: Ministry of Health, 2002.
3. Ministry of Health. Mortality and Demographic Data 2007. Wellington: Ministry of Health, 2010.
4. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89. http://dx.doi.org/10.1056/NEJMoa063070
5. Roche N. Where current pharmacological therapies fall short in COPD: symptom control is not enough. Eur Respir Rev 2007;16(105):98-104. http://dx.doi.org/10.1183/09059180.00010503
6. Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med 2005; 26(2):142-53. http://dx.doi.org/10.1055/s-2005-869535
7. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343(26):1902-09. http://dx.doi.org/10.1056/NEJM200012283432601
8. Cazzola M, Ciaprini C, Page CP, Matera MG. Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. Expert Opin Ther Targets 2007;11(10):1273-86. http://dx.doi.org/10.1517/14728222.11.10.1273
9. Walsh GM. Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Exp Rev Resp Med 2008;2(3):329-35. http://dx.doi.org/10.1586/17476348.2.3.329
10. Altose MD. Approaches to slowing the progression of COPD. Curr Opin Pulm Med 2003;9(2):125-30. http://dx.doi.org/10.1097/00063198-200303000-00006
11. Feldman C. The role of statins in respiratory diseases. Clin Pulm Med 2009;16(2):95-100. http://dx.doi.org/10.1097/CPM.0b013e31819b3a41
12. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61(8):729-34. http://dx.doi.org/10.1136/thx.2005.057976
13. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005;16(6):624-9. http://dx.doi.org/10.1097/01.mol.0000191913.16321.60
14. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009;18(114):1-11. http://dx.doi.org/10.1183/09059180.00005309
15. Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008;62(9):1373-8. http://dx.doi.org/10.1111/j.1742-1241.2008.01731.x
16. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131(4):1006-12. http://dx.doi.org/10.1378/chest.06-1997
17. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT. The use of statins and lung function in current and former smokers. Chest 2007;132(6):1764-71. http://dx.doi.org/10.1378/chest.07-0298
18. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47(12):2554-60. http://dx.doi.org/10.1016/j.jacc.2006.04.039
19. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009;10:45. http://dx.doi.org/10.1186/1465-9921-10-45
20. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29(2):279-83. http://dx.doi.org/10.1183/09031936.00106406
21. van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008;102(2):192-6. http://dx.doi.org/10.1016/j.amjcard.2008.03.038
22. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm 2009;9:32. http://dx.doi.org/10.1186/1471-2466-9-32
23. Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009;85:414-21. http://dx.doi.org/10.1136/pgmj.2008.078477
24. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest 2009;136(3):734-43. http://dx.doi.org/10.1378/chest.09-0194
25. Gelman A, Hill J. Causal inference using regression on the treatment variable. In: Data Analysis Using Regression and Multilevel/Hierarchical Models. New York: Cambridge University Press, 2007.
26. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2007.
27. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006;27(3):627-43. http://dx.doi.org/10.1183/09031936.06.00024605
28. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007;166(3):348-54. http://dx.doi.org/10.1093/aje/kwm070
29. Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008;100(2):134-9. http://dx.doi.org/10.1093/jnci/djm286
30. Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med 2008; 121(4):302-09. http://dx.doi.org/10.1016/j.amjmed.2007.12.011
31. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007;131(5):1282-8. http://dx.doi.org/10.1378/chest.06-0931
32. van Gestel YRBM, Hoeks SE, et al. COPD and cancer mortality: the influence of statins. Thorax 2009;64(11):963-7. http://dx.doi.org/10.1136/thx.2009.116731
33. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008;101(4):530-5. http://dx.doi.org/10.1016/ j.amjcard.2007.09.102